Maryann J. Kwa, MD
Further biomarker studies are needed to determine which patients may benefit from extended adjuvant endocrine therapy, in an effort to reconcile the high risk of recurrence in patients with estrogen receptor (ER)-positive breast cancer, said Maryann J. Kwa, MD.
State of the Science Summit™ on Breast Cancer, Kwa, an instructor in the Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discussed the optimal duration of endocrine therapy in the treatment of patients with early-stage ER-positive breast cancer.
OncLive: What does the landscape of early-stage ER-positive breast cancer look like?
: The first part of my presentation focused on a meta-analysis that looked at over 60,000 women with early-stage ER-positive breast cancer who had received an initial 5 years of adjuvant endocrine therapy. They followed these women out for up to 20 years to see what the risk of distant recurrence was. The summary of the meta-analysis was published in the New England Journal of Medicine
in 2017, and showed that there was a risk of distant recurrence all the way up to the 20-year mark. The risk of distant recurrence was 13% for small tumors and even greater for large tumors and involved lymph nodes.
... to read the full story